trending Market Intelligence /marketintelligence/en/news-insights/trending/P5Vfrfb9wl83W9Mqn2Oa4g2 content esgSubNav
In This List

Pfizer halts mid-stage trial for staph infection vaccine due to futility

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Pfizer halts mid-stage trial for staph infection vaccine due to futility

Pfizer Inc. has stopped a mid-stage clinical trial for a staph infection vaccine after an external group of experts determined that the trial would likely not meet its main goal.

The company said it is evaluating next steps for the development of the vaccine, meant to prevent Staphylococcus aureus infections in patients who are undergoing spinal fusion surgery.

The vaccine, called PF-06290510, was found to be safe in the planned interim analysis, and patients will complete the study's follow-up evaluations, the New York-based company said.